AstraZeneca PLC Logo

AstraZeneca PLC

ISIN: GB0009895292 | Ticker: AZN | LEI: PY6ZZQWO2IZFZC3IOL08
Sector: Health CareSub-Industry: Pharmaceuticals
Country: United Kingdom

About AstraZeneca PLC

Company Description

We are a global, science-led, patient-focused pharmaceutical company. We are tireless in seeking to realise the potential of what science can do.

We are focused on creating genuinely innovative medicines and improving access to them. In this way, we deliver the greatest benefit to patients, healthcare systems and societies globally. We have three priorities designed to deliver our growth through innovation strategy.

Oncology
We are leading a revolution in oncology to redefine cancer care. Our ambition is to provide cures for cancer in every form.

BioPharmaceuticals
We want to change the lives of billions of people living with chronic diseases for the better.

Rare Disease
Our mission is to transform the lives of people affected by rare diseases and devastating conditions.

Year founded

1999

Served area

Worldwide

Headquarters

1 Francis Crick Avenue, CB2 0AA Cambridge – United Kingdom

Financial statements

Download as Excel
Line item in (usd) 01.01.2019 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Assets N/A 61,377,000,000.00 66,729,000,000.00 105,363,000,000.00 96,483,000,000.00
Noncurrent Assets N/A 45,814,000,000.00 47,185,000,000.00 79,119,000,000.00 73,890,000,000.00
Property Plant And Equipment N/A 7,688,000,000.00 8,251,000,000.00 9,183,000,000.00 8,507,000,000.00
Goodwill N/A 11,668,000,000.00 11,845,000,000.00 19,997,000,000.00 19,820,000,000.00
Intangible Assets Other Than Goodwill N/A 20,833,000,000.00 20,947,000,000.00 42,387,000,000.00 39,307,000,000.00
Investment Accounted For Using Equity Method N/A 58,000,000.00 39,000,000.00 69,000,000.00 76,000,000.00
Other Noncurrent Receivables N/A 740,000,000.00 720,000,000.00 895,000,000.00 835,000,000.00
Deferred Tax Assets N/A 2,718,000,000.00 3,438,000,000.00 4,330,000,000.00 3,263,000,000.00
Noncurrent Derivative Financial Assets N/A 61,000,000.00 171,000,000.00 102,000,000.00 74,000,000.00
Noncurrent Investments Other Than Investments Accounted For Using Equity Method N/A 1,401,000,000.00 1,108,000,000.00 1,168,000,000.00 1,066,000,000.00
Current Assets N/A 15,563,000,000.00 19,544,000,000.00 26,244,000,000.00 22,593,000,000.00
Inventories N/A 3,193,000,000.00 4,024,000,000.00 8,983,000,000.00 4,699,000,000.00
Trade And Other Current Receivables N/A 5,761,000,000.00 7,022,000,000.00 9,644,000,000.00 10,521,000,000.00
Cash and cash equivalents N/A 5,369,000,000.00 7,832,000,000.00 6,329,000,000.00 6,166,000,000.00
Noncurrent Assets Or Disposal Groups Classified As Held For Sale Or As Held For Distribution To Owners N/A 70,000,000.00 0.00 368,000,000.00 150,000,000.00
Current Derivative Financial Assets N/A 36,000,000.00 142,000,000.00 83,000,000.00 87,000,000.00
Current Investments N/A 849,000,000.00 160,000,000.00 69,000,000.00 239,000,000.00
Equity 14,044,000,000.00 14,596,000,000.00 15,638,000,000.00 39,287,000,000.00 37,058,000,000.00
Issued Capital N/A 328,000,000.00 328,000,000.00 387,000,000.00 387,000,000.00
Retained Earnings N/A 2,812,000,000.00 5,299,000,000.00 1,710,000,000.00 -574,000,000.00
Share Premium N/A 7,941,000,000.00 7,971,000,000.00 35,126,000,000.00 35,155,000,000.00
Capital Redemption Reserve N/A 153,000,000.00 153,000,000.00 153,000,000.00 153,000,000.00
Merger Reserve N/A 448,000,000.00 448,000,000.00 448,000,000.00 448,000,000.00
Equity Attributable To Owners Of Parent N/A 13,127,000,000.00 15,622,000,000.00 39,268,000,000.00 37,037,000,000.00
Noncontrolling Interests N/A 1,469,000,000.00 16,000,000.00 19,000,000.00 21,000,000.00
Liabilities N/A 46,781,000,000.00 51,091,000,000.00 66,076,000,000.00 59,425,000,000.00
Noncurrent Liabilities N/A 28,664,000,000.00 30,784,000,000.00 43,482,000,000.00 33,132,000,000.00
Noncurrent Provisions N/A 841,000,000.00 584,000,000.00 956,000,000.00 896,000,000.00
Noncurrent Payables N/A 6,291,000,000.00 6,084,000,000.00 4,933,000,000.00 4,270,000,000.00
Deferred Tax Liabilities N/A 2,490,000,000.00 2,918,000,000.00 6,206,000,000.00 2,944,000,000.00
Noncurrent Recognised Liabilities Defined Benefit Plan N/A 2,807,000,000.00 3,202,000,000.00 2,454,000,000.00 1,168,000,000.00
Noncurrent Derivative Financial Liabilities N/A 18,000,000.00 2,000,000.00 45,000,000.00 164,000,000.00
Longterm Borrowings N/A 15,730,000,000.00 17,505,000,000.00 28,134,000,000.00 22,965,000,000.00
Current Liabilities N/A 18,117,000,000.00 20,307,000,000.00 22,594,000,000.00 26,293,000,000.00
Current Provisions N/A 723,000,000.00 976,000,000.00 768,000,000.00 722,000,000.00
Trade And Other Current Payables N/A 13,987,000,000.00 15,785,000,000.00 18,938,000,000.00 19,040,000,000.00
Current Derivative Financial Liabilities N/A 36,000,000.00 33,000,000.00 79,000,000.00 93,000,000.00
Current Borrowings And Current Portion Of Noncurrent Borrowings N/A 1,822,000,000.00 2,194,000,000.00 1,660,000,000.00 5,314,000,000.00
Line item in (usd) 01.01.2019/
01.01.2020
01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue 24,384,000,000.00 26,617,000,000.00 37,417,000,000.00 44,351,000,000.00
Revenue From Sale Of Goods 23,565,000,000.00 25,890,000,000.00 36,541,000,000.00 42,998,000,000.00
Depreciation Amortisation And Impairment Loss Reversal Of Impairment Loss Recognised In Profit Or Loss 3,762,000,000.00 3,149,000,000.00 6,530,000,000.00 5,480,000,000.00
Profit Loss From Operating Activities 2,924,000,000.00 5,162,000,000.00 1,056,000,000.00 3,757,000,000.00
Finance Income 172,000,000.00 87,000,000.00 43,000,000.00 95,000,000.00
Finance Costs 1,432,000,000.00 1,306,000,000.00 1,300,000,000.00 1,346,000,000.00
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method -116,000,000.00 -27,000,000.00 -64,000,000.00 -5,000,000.00
Profit Loss Before Tax 1,548,000,000.00 3,916,000,000.00 -265,000,000.00 2,501,000,000.00
Income Tax Expense Continuing Operations 321,000,000.00 772,000,000.00 -380,000,000.00 -792,000,000.00
Profit (loss) 1,227,000,000.00 3,144,000,000.00 115,000,000.00 3,293,000,000.00
Profit Loss Attributable To Owners Of Parent 1,335,000,000.00 3,196,000,000.00 112,000,000.00 3,288,000,000.00
Profit Loss Attributable To Noncontrolling Interests -108,000,000.00 -52,000,000.00 3,000,000.00 5,000,000.00
Line item in (usd) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) 1,227,000,000.00 3,144,000,000.00 115,000,000.00 3,293,000,000.00
Adjustments For Decrease Increase In Inventories -316,000,000.00 -621,000,000.00 1,577,000,000.00 3,941,000,000.00
Other Adjustments For Noncash Items 378,000,000.00 -276,000,000.00 95,000,000.00 -692,000,000.00
Cash Flows From Used In Operations 4,861,000,000.00 7,094,000,000.00 8,427,000,000.00 12,280,000,000.00
Interest Paid Classified As Operating Activities 774,000,000.00 733,000,000.00 721,000,000.00 849,000,000.00
Income Taxes Paid Refund Classified As Operating Activities 1,118,000,000.00 1,562,000,000.00 1,743,000,000.00 1,623,000,000.00
Cash Flows From Used In Operating Activities 2,969,000,000.00 4,799,000,000.00 5,963,000,000.00 9,808,000,000.00
Cash Flows Used In Obtaining Control Of Subsidiaries Or Other Businesses Classified As Investing Activities 0.00 0.00 9,263,000,000.00 48,000,000.00
Other Cash Payments To Acquire Interests In Joint Ventures Classified As Investing Activities 74,000,000.00 8,000,000.00 92,000,000.00 26,000,000.00
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities 37,000,000.00 106,000,000.00 13,000,000.00 282,000,000.00
Purchase Of Property Plant And Equipment Classified As Investing Activities 979,000,000.00 961,000,000.00 1,091,000,000.00 1,091,000,000.00
Proceeds From Sales Of Intangible Assets Classified As Investing Activities 2,076,000,000.00 951,000,000.00 587,000,000.00 447,000,000.00
Purchase Of Intangible Assets Classified As Investing Activities 1,481,000,000.00 1,645,000,000.00 1,109,000,000.00 1,480,000,000.00
Proceeds From Other Longterm Assets Classified As Investing Activities 18,000,000.00 1,381,000,000.00 9,000,000.00 42,000,000.00
Purchase Of Other Longterm Assets Classified As Investing Activities 13,000,000.00 119,000,000.00 184,000,000.00 45,000,000.00
Interest Received Classified As Investing Activities 124,000,000.00 47,000,000.00 34,000,000.00 60,000,000.00
Other Inflows Outflows Of Cash Classified As Investing Activities 194,000,000.00 745,000,000.00 96,000,000.00 -114,000,000.00
Cash Flows From Used In Investing Activities -657,000,000.00 -285,000,000.00 -11,058,000,000.00 -2,960,000,000.00
Proceeds From Issuing Shares 3,525,000,000.00 30,000,000.00 29,000,000.00 29,000,000.00
Proceeds From Borrowings Classified As Financing Activities 500,000,000.00 2,968,000,000.00 12,929,000,000.00 0.00
Repayments Of Borrowings Classified As Financing Activities 1,500,000,000.00 1,609,000,000.00 4,759,000,000.00 1,271,000,000.00
Payments Of Lease Liabilities Classified As Financing Activities 186,000,000.00 207,000,000.00 240,000,000.00 244,000,000.00
Dividends Paid Classified As Financing Activities 3,592,000,000.00 3,572,000,000.00 3,856,000,000.00 4,364,000,000.00
Other Inflows Outflows Of Cash Classified As Financing Activities -516,000,000.00 288,000,000.00 -276,000,000.00 74,000,000.00
Cash Flows From Used In Financing Activities -1,765,000,000.00 -2,203,000,000.00 3,649,000,000.00 -6,823,000,000.00
Increase (decrease) in cash and cash equivalents before effect of exchange rate changes 547,000,000.00 2,311,000,000.00 -1,446,000,000.00 25,000,000.00
Effect Of Exchange Rate Changes On Cash And Cash Equivalents 5,000,000.00 12,000,000.00 -62,000,000.00 -80,000,000.00
Cash and cash equivalents 5,369,000,000.00 7,832,000,000.00 6,329,000,000.00 6,166,000,000.00

Please note that some sums might not add up.

Filings & Publications

2023

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2022

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
08.03.24 Pascal Soriot Other Other EUR 0.00
05.03.24 Pascal Soriot Other Other EUR 0.00
04.03.24 Pascal Soriot Other Other EUR 11,076,196.32
04.03.24 Aradhana Sarin Other Other EUR 5,960,391.25
12.12.23 Anna Manz Other Buy EUR 49,623.16
22.11.23 Michel Demare Other Buy EUR 101,700.00
21.11.23 Michel Demare Other Buy EUR 101,052.24
28.04.23 Michel Demare Other Buy EUR 234,020.00
23.03.23 Pascal Soriot Other Other EUR 0.00
06.03.23 Pascal Soriot Other Other EUR 0.00

Capital markets information

ISIN

GB0009895292

LEI

PY6ZZQWO2IZFZC3IOL08

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Pharmaceuticals

Sub-Industry

Pharmaceuticals

Listed Stock Exchange

London Stock Exchange

Stock Index

FTSE 100

OMX Stockholm 30

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.